To evaluate if the impact of targeted ICB on MSH2 KO tumor growth limitation was due to immune infiltration, we examined the immune subsets that differentially infiltrate MSH2 KO and WT tumors in mice after anti-TIM3/TIGIT/LAG3, with or without anti-PD-1 therapy (Extended Figure Figure 16 A/B, Extended Figure 17 A/E). The gene discussed is TIGIT; the disease is neoplasm.